JNJ Stock Holds Near Recent Highs as Q2 Earnings Exceed Expectations

Johnson & Johnson's stock price has held steady near recent highs of around $275 after the company delivered a strong Q2 2026, exceeding expectations with 6.6% year-over-year revenue growth and 4.7% earnings per share (EPS) increase.

The company's sales rose to $25.3 billion in Q2 2026, surpassing $25 billion for the first time in its history. Adjusted EPS came in at $2.90, roughly $0.05 above consensus estimates of $2.85.

Johnson & Johnson increased its full-year 2026 guidance for a second consecutive quarter, lifting estimated reported sales to around $101.1 billion and adjusted EPS to $11.68. This represents approximately 7.3% revenue growth and 8.2% EPS growth at the midpoint compared to the prior year.

The company's diversified business model and stable cash generation have contributed to its strong financial performance, with a net margin of 21.48% in Q2 2026 and return on equity of 32.42%. However, key risks include regulatory or legal developments affecting the company's legacy product portfolio and competitive pressure in pharmaceuticals and medical devices.